Navigation Links
Gleevec Pushes Advanced Melanoma Into Remission

Woman's case first showing the cancer may have an Achilles' heel, report suggests

THURSDAY, April 17 (HealthDay News) -- The cancer drug Gleevec has forced metastatic melanoma into remission for the first time, report researchers at the Dana-Farber Cancer Institute in Boston.

The case involves a 79-year-old woman with melanoma tumors in several parts of her abdomen. The tumor cells carried an abnormality in a gene called KIT, so the patient was enrolled in a clinical trail of the drug imatinib (Gleevec), which targets the KIT gene.

Four weeks after the woman started therapy, there was dramatic reduction in tumor size and metabolism. Two of the tumor masses had vanished, and several others were much smaller. After four months, the tumors were still in check and, nine months later, the women was still taking the drug and her condition remained stable.

The report was published in the April 20 issue of the Journal of Clinical Oncology.

"This is the first proof of principle that we can find an Achilles' heel in melanoma and by targeting that gene with a drug, cause the [tumor cells] to die. It is especially exciting because there haven't been any effective treatments for melanoma patients with metastatic disease," study author Dr. Stephen Hodi said in a prepared statement.

He said this case may involve just one patient, but should inspire new hope in the fight against melanoma. Because previous research failed to identify any genetic weak point that could be targeted to stop melanoma cell growth, some researchers believed that no such Achilles' heel existed for melanoma cells. The discovery of this one suggests there may be others.

"Dramatic remissions in metastatic melanoma are something that, as physicians, we've rarely seen. Confirming these results will require enrolling additional patients in clinical trials -- something we're actively working to accomplish," Hodi said.

More information

The U.S. National Cancer Institute has more about melanoma.

-- Robert Preidt

SOURCE: Dana-Farber Cancer Institute, news release, April 17, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Gleevec May Disrupt Ovarian Function
2. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
3. Gleevec, the targeted cancer pill, delivers more good news to patients
4. Arizona Senate Pushes for Smoking Cessation Treatments for State Medicaid Beneficiaries
5. Pedometer Pushes People to Walk More
6. Depression Pushes Middle-Aged Workers to Retire
7. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
8. HHS Names First Director of the Biomedical Advanced Research Development Authority
9. Advanced Life Sciences to Host Conference Call to Discuss April 7th Meeting with FDA
10. Cato Research Ltd. and Advanced Targeting Systems, Inc. Partner to Develop SP-SAP for Chronic Pain
11. Body Mass Index may serve as prognostic tool for advanced, aggressive breast cancers
Post Your Comments:
(Date:11/25/2015)... BROOK, Ill. (PRWEB) , ... November 25, 2015 ... ... larger and potentially more aggressive than those found on mammography, according to a ... MRI findings of additional cancers not seen on mammography may necessitate a change ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical ... more about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared ... thicker and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... ... Dental professionals who would like to become more proficient on their knowledge of ... Advanced Implant Mentoring (AIM) CE course. Courses will be held on December 3rd, 4th ... Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce that individuals ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
(Date:11/26/2015)... 26, 2015 --> ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... found that immunotherapy can be efficiently combined with photodynamic ...
Breaking Medicine Technology: